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Herein we report the development of a non-viral lipid-complexed PRINT® (particle replication in
non-wetting templates) protein particle system (LPP particle) for RNA replicon delivery with a
view towards RNA replicon-based vaccination. Cylindrical bovine serum albumin (BSA) particles
(diameter (d) 1 µm, height (h) 1 µm) loaded with RNA replicon and stabilized with a fully
reversible disulfide cross-linker were fabricated using PRINT technology. Highly efficient
delivery of the particles to Vero cells was achieved by complexing particles with a mixture of 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) lipids. Our data suggest that: 1) this lipid-complexed protein
particle is a promising system for delivery of RNA replicon-based vaccines, and 2) it is necessary
to use a degradable cross-linker for successful delivery of RNA replicon via protein-based
particles.
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INTRODUCTION
Nucleic acids offer a unique opportunity for vaccination and have emerged as excellent
candidates for the treatment of cancers and infectious diseases.1–4 Compared with traditional
protein-based vaccination strategy, direct immunization with RNA or DNA has the
advantages of the simplicity and purity with which they can be produced, as well as coding
for a single protein of interest (i.e. an antigen) at high levels in a reproducible manner,
potentially triggering immune response in both cellular and humoral branches.5–7
To protect nucleic acids from enzyme degradation and facilitate entry into cells, many
delivery techniques including physical techniques such as the gene gun and
electroporation,4, 8 nonviral delivery vehicles such as liposomes and cationic polymers,9–11
and viral vector-based carriers,12 have been extensively explored. However, despite decades
of research efforts, commercial products for human use are still unavailable.
An RNA replicon is an important form of a nucleic acid-based vaccine and is derived from
either positive- or negative-strand RNA viruses, from which the gene sequences encoding
structural proteins are replaced by mRNA encoding antigens of interest as well as the RNA
polymerase for RNA replicon replication and transcription.13–15 RNA replicons can be
regarded as “disabled” virus vectors that are capable of amplifying within the cytoplasm of
host cells for a prolonged period but are unable to produce infectious progeny.16, 17
Compared with DNA vaccines, which are also under active investigation, an RNA replicon-
based vaccine has two advantages: first, it is capable of replicating exclusively in the
cytoplasm of host cells, thus avoiding the requirement of nuclear entry which represents a
daunting hurdle in DNA delivery. By eliminating the dependence on cellular transcription
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machinery and transport of nucleic acids to and from the nucleus, an RNA replicon is
potentially a more efficient form of nucleic acid vaccine.18–20 Secondly, an RNA replicon
has superior biosafety features, which is crucial for vaccination purposes. Compared with
DNA, RNA replicon can avoid the potential integration into the genome of host cells and
also prevent generation of anti-DNA antibodies, both of which may affect the host cell’s
gene expression in an uncontrollable manner and thus represent incalculable risks.21 RNA
replicon combines the safety characteristics of inactivated vaccines with the superior
immunogenicity of live, attenuated vaccines.
Studies have shown that RNA replicon-based vaccination is highly effective for generating
cellular and protective immune responses, but has been delivered mainly as naked RNA
transcribed in vitro or via viral vectors. 13, 22 The practical utility of viral vectors, however,
is limited by manufacturing considerations, cost-effectiveness, and potential adverse health
effects.23, 24 The delivery of RNA replicon via synthetic vectors is a highly attractive
approach. However, RNA replicons usually have very large sizes (~ 9 kb) compared to
mRNA (~2 kb), which adds additional challenge to the development of drug delivery
vehicles. There has been very limited data published on nonviral delivery of RNA replicons
and it was not until recently that Geall et al. demonstrated the delivery of RNA replicons via
liposome nanoparticles.25 In our previous work, we demonstrated the delivery of RNA
replicon to Vero cells via PRINT protein particles with the assistance from a TransIT®-
mRNA transfection reagent (TransIT).26 However, we encountered batch-to-batch
reproducibility issues when TransIT was used as a transfection reagent. TransIT is also cost
prohibitive especially for large-scale studies. In addition, at the optimal dosage
recommended by manufacturer, TransIT can only deliver particles at very low
concentrations, which represents a bottleneck for effective RNA replicon delivery for
vaccine purposes (SI, issues with TransIT for transfection of PRINT protein particles).
These issues with TransIT motivated us to find another reagent that can facilitate cell uptake
and particle transfection. To avoid this limitation, we explored lipids as a much more
efficient and effective transfection reagent for RNA replicon loaded PRINT particles, which
can be potentially developed into a next generation vaccine. In this study, we also
investigated in detail the loading of RNA replicon into PRINT particles, the stabilization of
RNA replicon-loaded particles, as well as the role of a reversible disulfide linker in delivery
of RNA replicon via protein-based particles.
EXPERIMENTAL SECTION
Materials
Bovine serum albumin and Fluorsave™ reagent were from Calbiochem. Tyramine and 1'-
Carbonyldiimidazole was purchased from Sigma Aldrich. BCA protein assay reagent was
from Thermo Scientific. DIC as synthesized as previously published in ref. 26. Alexa fluor
488® labeled Bovine serum albumin, Alexa Fluor® 546 goat anti-rabbit IgG (H+L) and
Quant-iT ™ RNA assay kit were purchased from invitrogen. Anti-Chloramphenicol
Acetyltransferase antibody was purchased from Abcam. TransIT®-mRNA transfection kit
was purchased from Mirus. α-D-Lactose and glycerol were purchased from Acros. 1,2-
dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP), and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) were from Avanti polar lipids, Inc.
Cells and culture
Cells were maintained at 37 °C in an atmosphere containing 5% CO2. Vero cells were
grown in Minimum Essential Medium (MEM; Invitrogen, Carlsbad, CA) supplemented with
5% fetal bovine serum (FBS, HyClone, Logan, UT), MEM non-essential amino acid
solution (Invitrogen) and antibiotic–antimycotic (Invitrogen). A549 cells were maintained at
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37 °C in an atmosphere containing 5% CO2. The cells were grown in Dulbecco’s Minimum
Essential Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS, HyClone, Logan, UT), and antibiotic–antimycotic (Invitrogen).
RNA replicon construction and particle preparation
Construction of CAT, Luciferase and HA RNA replicons and preparation of RNA replicon
loaded BSA-based particles, preparation of RNA replicon loaded Alexa fluor 488® labeled
BSA particles and particle crosslinking reaction followed the procedures described in [ 26].
RNA replicon extraction from un-crosslinked particles and DIC-crosslinked particles
For particles prior to crosslinking, 50 µL of PBS was added to dissolve 0.15 mg particles.
For crosslinked particles, 50 µL of PBS containing 10 mM dithiothreitol (DTT) was added
to dissolve 0.15 mg particles. A Qiazol-chloroform extraction procedure was used to extract
RNA replicon from the RNA replicon-BSA mixture. The RNA pellet acquired was
dissolved in 20 µL of DEPC-treated water. For un-crosslinked particles, 5 µL of sample was
loaded on the gel and10 µL of sample was loaded for cross-linked particles.
Agarose gel electrophoresis
Agarose gel was prepared by dissolving agrasose in 1× NorthernMax®-Gly gel preparation
and running buffer (Ambion) at 1 wt%. Typically, 5 µL of sample was mixed with 5 µL of
water (or 10 µL of sample) and 10 µL of NorthernMax®-Gly load dye (Ambion) and heated
at 50 °C for 10 min before loading onto the gel. The gel was then run in 1× NorthernMax®-
Gly gel preparation and running buffer (Ambion) at 70 V for 35 min before being imaged by
a GE ImageQuant LAS 4000 biomaolecular imager.
Preparation of lipid-complexed particles
DOTAP:DOPE (75:25) was prepared by first dissolving 1 mg of DOTAP and 1 mg of
DOPE in 20 µL of trifluoroethanol (TFE) separately and mixing the two components
according to the above ratio. Then water was added to achieve a concentration of 3 mg/mL.
RNA replicon-loaded particles were prepared and cross-linked as previously described and
were resuspended in isopropanol at 1 mg/mL. Particles were pelleted down using a
minicentrifuge and isopropanol was removed. DOTAP/DOPE (75:25) solution (3 mg/mL)
were added to the vial to achieve a particle concentration of 1 mg/mL and mixed by
pippeting. The particle-lipid solution was incubated at room temperature for 1h. The
particles were then pelleted down using a minicentrifuge and supernatant was then removed.
The particles were washed three times through centrifugation with water at a particle
concentraion of 1 mg/mL and finally dispersed in water with 5 wt% dextrose at 1 mg/mL.
Quantification of DOTAP/DOPE on LPP particles
The amount of DOTAP and DOPE were measured using HPLC (Agilent Technologies
1260) with a C18 rapid resolution column (Zorbax Eclipse plus, 4.6 × 100 mm, 3.5 micron)
and a column temperature of 40 °C was used. A mobile phase of water and methanol on a
gradient from 85% of methanol to pure methanol over 10 min followed by pure methanol for
another 2 min with a flow rate of 2 mL/min was employed with a detection temperature of
50 °C on the ELSD (Agilent Technologies 1260). The DOTAP peak appeared at 8.0 minutes
and the DOPE peak appeared at 9.8 minutes. The peak areas were compared to the DOTAP
and DOPE standard curves to determine the concentration of lipids in the solution. The
amounts of DOTAP and DOPE on the LPP particles were calculated by subtracting the
amount of lipids in the supernatants and washes from the original lipid solution.
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Physical Characterization of the PRINT Protein Particles
After the cross-linking reaction followed by incubation in water for 24h at room
temperature, the particles were deposited on a glass slide, coated with palladium/gold and
imaged by a scanning electron microscopy (Hitachi modelS-4700). The hydrodynamic
diameters of the PRINT particles were measured by dynamic light scattering (Brookhaven
Instruments Inc., 90Plus). For zeta potential measurements, the particles were dispersed in 1
mM potassium chloride at a concentration of 20 µg/ml and tested by a Zetasizer Nano
Analyzer (Malvern Instruments Inc., Nano Zetasizer).
Analysis of luciferase and HA expression
The dosing of LPP particles and preparation of cell lysates followed procedures described in
reference 26. Luciferase assay was carried out according to the manufacturer's instructions.
The relative bioluminescence was calculated using following method: 
Where Ar: the relative bioluminescence. Aa: the bioluminescence acquired by plate reader
for samples dosed with RNA replicon or particles. Ac: the bioluminescence acquired by
plate reader for untreated cells. Vero cells plated at on cover slips in 6-well dishes and
grown for 24 hours. Cells were treated with LPP particles for 4h, medium was aspirated and
replaced with fresh medium for 44h. Cells were then washed three times with ice cold
1×PBS and fixed with cold (−20°C) acetone/methanol (1:1 mix) for 5 minutes. Cells were
washed in ice cold 1×PBS 3 times. For HA detection, cells were then incubated in primary
antibody (Rabbit IgG, Immune Technology Corp, cat# IT-003-SW) for 1 hr at 37°C in the
dark, cells were then washed with three times with 1XPBS and incubated in secondary
Alexa Fluor® 546 goat anti-rabbit IgG (H+L) (cat #A11010, Invitrogen) for 1hr at RT in
dark. For luciferase detection, cells were incubated with primary antibody conjugated with
FITC (US Biological, cat# L5999-09A) for 1h at 37°C in the dark. Washed twice in PBS
and mounted with Fluorsave™ reagent. Samples were then analyzed by confocal
microscopy. Confocal images were acquired using a Ziess 710 laser scanning confocal
imaging system (Olympus) fluorescence microscope fitted with a PlanApo 60× oil objective
(Olympus). The final composite images were created using Adobe Photoshop CS (Adobe
Systems, San Jose, CA).
Cytotoxcity study of RNA loaded LPP particles
Typically, 5×103 Vero cells were plated into 96 well tissue cultured treated plates 18–24 h
prior to assay. The LPP particles were dosed to cells as previously described. The mixture
was subsequently incubated with Vero cells for 4h at 37 °C and the non-internalized
particles were removed. The cells were further incubated for another 24h at 37 °C before
ATP was quantitated using the CellTiter-G10 Luminescent Cell Viability Assay (Promega)
following vendor’s protocol.
RESULTS
1) Encapsulation of RNA Replicon and Stabilization of the Particles
We have previously demonstrated that RNA replicon can be incorporated into cylindrical
bovine serum albumin (BSA) PRINT particles (diameter (d) 1 µm, height (h) 1 µm) by
mixing an RNA replicon with BSA, lactose and glycerol to form a preparticle solution that
can flow into the cavities of the PRINT mold when heated (SI, fabrication of RNA replicon-
incorporated PRINT particle).26 RNA replicon is a single stranded RNA with low stability.
Maintaining its integrity in the process of PRINT particle fabrication is essential. We first
investigated the influence of temperature used for particle fabrication on the biological
activity of RNA replicon. A model RNA replicon encoding chloramphenicol acetyl
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transferase (CAT) was chosen in this study because CAT is a bacterial enzyme and
exogenous for mammalian cells and the assays to quantify CAT activity have been well
established. Typically, 1 wt% of CAT RNA replicon was formulated with 37 wt% of BSA,
37 wt% of lactose and 25 wt% of glycerol. This dry mixture was processed into cylindrical
albumin particles by using two temperatures on the heated laminator roller: 60°C vs. 148°C.
The particles were dissolved in phosphate buffered saline (PBS) and followed by extraction
of RNA replicon from the BSA-RNA replicon mixture. It should be noted that the un-
crosslinked particles used in this experiment were readily soluble in water. The integrity of
the extracted RNA replicon was first evaluated using agarose gel electrophoresis, as shown
in Figure 1a. Electrophoresis analysis showed that only RNA replicon encapsulated at 60°C
displayed a bright tight band at the same position as the untreated RNA replicon. Below the
band, there was some smearing representing the degraded RNA replicon, but the brightness
of the smearing was significantly weaker than the band. By contrast, the RNA replicon
encapsulated at 148 °C mainly showed smearing. The integrity of the RNA replicon was
further accessed by a CAT ELISA assay after the RNA replicon was transfected into Vero
cells, a kidney epithelial cell line developed from an African green monkey, using TransIT.
Results showed that RNA replicon encapsulated at 148°C showed very minimal biological
activity and RNA extracted from particles fabricated at 60°C produced similar protein
expression levels to an untreated RNA replicon control (Figure 1b). The results indicated
that for encapsulation of RNA replicon into BSA PRINT particles, lower temperature is
more favorable for maintaining the integrity of the RNA cargo. When PRINT replicon
particles are processed at 60°C, some of the RNA replicon was damaged, however, the
amount of degraded RNA was so minimal that no difference was discernable in the CAT
ELISA assay. After the harvest and purification processes using isopropanol, the particles
fabricated at 60°C were determined to contain 1.5±0.1 wt% of RNA replicon in the final
particle composition (Table S1). Given the size of the particles and the level of loading of
RNA, this corresponds to approximately 2000 copies of the RNA replicon per particle
(calculated based on a particle density of 1.0 g/mL).
The site of action for RNA replicon is cytoplasm, which is known for its high concentration
of reduced glutathione (GSH) compared to the extracellular environment (GSH intracellular
concentration between 5 mM and 15 mM).27 Therefore, a disulfide-based cross-linker was
chosen to cross-link the particle to act like a Trojan Horse (an image of the particles after
incubation in water is shown in Figure 2a). We used dithio-bis(ethyl 1 H-imidazole-1-
carboxylate) (DIC) as the cross-linker to stabilize the protein particles in aqueous solutions
(SI, Figure S5). This cross-linker was developed by our group and, compared to a
commercially available disulfide linker dithiobis[succinimidyl propionate] (DSP), has
several advantages for protein particle stabilization for RNA replicon delivery.26 Imidazoles
as the leaving groups enhanced the reaction selectivity for amines over hydroxyl groups,
which is essential to maintain the integrity of RNA replicon in the cross-linking procedure.
Furthermore, DIC is a “traceless” reversible cross-linker, which does not leave any
molecular pendants after disulfide cleavage. A truly reversible chemistry has many benefits
for the delivery of RNA replicon. It releases the amino groups in its original form and avoids
the unknown immune response towards novel antigens. Additionally, even if the amine
functionalities on nucleobases were cross-linked by DIC, due to the fully reversible nature
of the cross-linker, the nucleobases should revert to its original state upon disulfide cleavage
if DIC is used.
To assess the integrity of the RNA replicon after the cross-linking step, particles were
dissolved in 10 mM dithiothreitol (DTT) solution and the RNA replicon extracted from the
mixture was again evaluated by agarose gel electrophoresis (Figure 2b). The agarose
electrophoresis gel results demonstrate that after the cross-linking step there is still a band
representing intact RNA replicon associated with particles although there was also some
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smearing below the band. The RNA replicon integrity was confirmed by induced expression
of CAT protein after transfection to Vero cells (SI, Characterization of cross-linked BSA
particles). We further analyzed the impact of cross-linking reaction on the integrity of the
RNA replicon. These results suggest that the amount of CAT protein expressed by RNA
replicon treated with the cross-linker is comparable to untreated RNA replicon (SI, Figure
S6). This indicates that the cross-linking reaction is RNA-friendly. More information about
release of RNA from cross-linked protein particles is available in SI (Characterization of
cross-linked BSA particles, Figure S7).
2) Delivery of CAT RNA Replicon-loaded Particles
Due to the isoelectric point of BSA (pI = 4.75), the cross-linked BSA particles with RNA
replicons are negatively charged (ζ potential = −15.4 ± 1.0 mV). Based on the previous
studies from our group and other groups, cells generally preferentially internalize positively
charged particles through a non-specific electrostatic interactions between the positively
charged particles and the negatively charged cell membrane. 28 DOTAP and DOPE have
been widely used as transfection reagents for gene delivery and they also enjoy the
advantage of being commercially available and cost-effective. 29, 30 The introduction of
lipids is also expected to enhance the endosomal escape of BSA particles, which is the major
roadblock for RNA replicon delivery.
A lipid mixture of DOTAP:DOPE (75:25, weight ratio) was mixed with the RNA replicon
loaded BSA particles and incubated for 1h at room temperature to enable the lipids to
complex with the particles. The particles were washed three times with water through
centrifugation to remove excess lipids. High-performance liquid chromatography (HPLC)
coupled with evaporative light scattering detection (ELSD) was used to determine the
amount of lipids complexed with BSA RNA replicon particles and it was found that 0.46 ±
0.06 mg of DOTAP and 0.11 ±0.02 mg of DOPE were associated with 1 mg of particles (the
actual ratio of DOTAP:DOPE=80:20). The interaction between lipids and the cross-linked
particles was studied and the results indicated that hydrophobic interaction contributes to the
lipid-particle complexation, and ionic interaction does not (SI, Table S2). From the results,
we also suspect that lipids are not only present on the surface of the negatively-charged
particles, but also penetrate to the interior of the particles.
The lipid-complexed PRINT protein particles (LPP particles) achieved a positively charged
surface (ζ potential = +29.3 ± 2.5 mV) and were subsequently incubated with Vero cells for
4 h at 37 °C and the non-internalized particles were removed (SI,Table S3). The cells were
further incubated for another 24h at 37 °C to allow for the expression of CAT protein. The
LPP particle delivery of the CAT protein was comparable to the same amount of RNA
replicon directly delivered by TransIT (Figure 3). Compared to our previous work which
uses TransIT to assist particle transfection ,26 LPP particles showed substantial improvement
in the amount of CAT protein that can be produced by Vero cells, and achieved dose
dependence up to 60 µg/mL. Utilizing TransIT as the transfection reagent for the protein
particles can only effectively deliver particles at particle concentrations below 2 µg/mL. In
addition, LPP particles can deliver RNA replicon in a highly reproducible manner.
To study the necessity of the disulfide cross-linker in the delivery of RNA replicon via
protein particles, particles cross-linked with a non-degradable linker 2,2'-oxybis(ethane-2,1-
diyl) bis(1H-imidazole-1-carboxylate) (OEDIC) under the same reaction condition as DIC
was also investigated. Because both DIC and OEDIC have imidazole leaving groups and the
concentrations of cross-linkers and the reaction time were held constant, therefore we expect
the BSA particles cross-linked with DIC and OEDIC to have similar cross-linking density. It
was observed that very minimal protein was expressed with particles cross-linked by
OEDIC compared to particles cross-linked by the disulfide cross-linker DIC. This result
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demonstrated that 1) a disulfide linker is important to achieve cytoplasm release of RNA
replicon; and 2) the intracellular protease were not responsible for the BSA particle
degradation and RNA replicon release at least during the 24-h time frame of our assay.
Therefore, the disulfide linker DIC can not only stabilize particles in the process of delivery,
but also efficiently release RNA replicon at the ultimate site of action.
Analysis using confocal microscopy was carried out to visually confirm the generation of
CAT protein. Fixed and permeabilized Vero cells treated with LPP particles were stained
with a primary antibody that binds specifically to CAT protein, and further treated with dye-
labeled secondary antibody. Compared to untransfected cells, cells transfected with DIC-
crosslinked RNA replicon-containing particles showed intense fluorescence, indicating for
high levels of expression of CAT proteins in those cells (Figure 4). A 3D image of encoded
CAT protein and the LPP particles inside the Vero cells was captured and showed in Figure
S8. Cells transfected with OEDIC-crosslinked RNA replicon-containing particles showed no
trace of CAT protein.
The viability of Vero cells was evaluated after the 24-h CAT protein expression (Figure 5).
Cytocompatibility was maintained at lower dosing concentrations; however, the LPP
particles appeared to be slightly toxic at particle concentration of 60 µg/mL. The toxicity
may be attributed to the lipids which alone cause cell death at higher dosing concentrations.
3) Delivery of Luciferase RNA replicon and Influenza hemagglutinin (HA) RNA replicon
To show that RNA replicons encoding different proteins can be encapsulated and delivered
within the same LPP particle, RNA replicons encoding a luciferase protein and a
therapeutically relevant antigen influenza hemagglutinin (HA) were incorporated into the
particles and delivered to cells via aforementioned methods. Both Luciferase and HA are
exogenous for the cell lines investigated and their quantification methods have been well
established. HA is a type of integral envelope proteins found on the surface of the influenza
virus and is a critical antigen in eliciting protection against influenza virus challenges.31 The
bioluminescence generated by luciferase RNA replicon-loaded LPP particles was
comparable to the same amount of RNA replicon directly delivered by TransIT (Figure 6a).
The generation of luciferase protein and the advantage of LPP particles over particles mixed
with TransIT were also confirmed by confocal microscopy (Figure 6b and Figure S9). Here
we further explored the necessity of using PRINT particles for delivery of RNA replicon.
Compared to using DOTAP/DOPE alone for RNA replicon transfection, LPP particle-
mediated delivery showed five times higher protein expression (SI, Comparison between
DOTAP/DOPE only and LPP particles). In addition to Vero cells, LPP particles also
delivered luciferase-encoding RNA replicon to an A549 cell line derived from
adenocarcinomic human alveolar basal epithelial cells, with a lower protein expression level
compared to Vero cells (Figure 6c).
The ability of a cross-linked BSA particle matrix to act as a shield to protect the delicate
RNA cargo from degradation especially from endogenous nucleases is an important design
characteristic that we were hoping to observe. To test this hypothesis, the RNA replicon
encapsulated into the LPP particles was treated with RNase A as a function of RNase A
concentration for 1h at 37 °C (SI, Figure S11). The results indicated that the LPP particles
successfully protected the RNA replicon from degradation by RNase A. In contrast, the
naked RNA was completely degraded after incubation with RNase A of the same
concentration under the same condition (SI, Figure S12).
The cells treated with HA replicon-loaded LPP particles were observed to show HA
expression, indicating successful delivery of HA RNA replicon to the Vero cells (Figure 7).
These results suggest that PRINT is a general approach for delivering RNA replicons with
Xu et al. Page 8













straightforward incorporation of different cargos and can work in a “plug and play” manner,
which is particularly important for development of new vaccines for epidemic diseases.
DISCUSSION
The PRINT technique developed in our lab is a platform that enables the generation of
engineered micro- and nanoparticles having precisely controlled properties including size,
shape, modulus, chemical composition and surface functionality for drug delivery
applications. 26, 28, 32–35 We have demonstrated that PRINT particles can be designed to
impact biodistribution,36, 37 lung deposition,38 cell internalization profiles,28, 32 and to
deliver therapeutic cargos.30, 39 PRINT is also amenable to continuous roll-to-roll
fabrication techniques that enable the scale-up of the particle fabrication under good
manufacturing practice (GMP) compliance. Using PRINT, a variety of cargos can be
incorporated through inclusion in the particle matrices in a “plug-and-play” manner. This
can potentially speed up the development of new vaccines, which is particularly important in
the vaccination against epidemic diseases. PRINT allows for the precise and simultaneous
control over all the parameters that are essential to protect and deliver the RNA replicon and
provides a platform for development of safe and effective vaccines against a wide variety of
diseases.
For delivery of mRNA or RNA replicons, the most-frequently used synthetic strategies
include liposomes,12, 25, 40 polyplexes,29, 41 or surface absorption onto cationic particles,11
etc. The LPP particle system is a unique approach in that the RNA replicon is encapsulated
into particles chemically stabilized by a reversible linker, allowing the RNA to be
selectively released in the cytoplasm of cells. This design affords robust protection for the
RNA replicon against endogenous nucleases. Here by comparing with a control non-
degradable linker, the reversible disulfide linker was clearly demonstrated to play a vital role
in the successful delivery of RNA replicon. This result may provide important information
for design of particle systems for cytoplasmic delivery of therapeutics including proteins,
peptides or other nucleic acids. In this initial proof-of-concept study, we used BSA as the
matrix of the particles. We are aware that humans will generate an immune response to BSA
and this may result in adverse health effects upon multiple doses. In the future work, human
serum albumin, synthetic polymers or polypeptides can be used as the particle matrix to
reduce this risk.
CONCLUSION
Herein, a novel method for the delivery of RNA replicon via lipid-complexed PRINT
protein (LPP) particles was demonstrated. This particle fabrication method, built on the
PRINT technology platform, not only allows for the fabrication of particles of controlled
sizes and shapes, but also was gentle enough to encapsulate RNA replicon without
abolishing their biological activity. A disulfide cross-linker was essential to not only
maintaining the BSA-based particles from dissolution in aqueous media, but was also
essential in degrading in the intracellular reducing environment to enable release of the RNA
replicon cargo. By complexing the particles with DOTAP/DOPE lipids, the particles were
able to be successfully transfected to Vero cells and encoded protein was expressed via
delivery of PRINT particles. The reversible disulfide linker was demonstrated to play a vital
role in the successful delivery of RNA replicon. RNA replicons encoding different proteins
including luciferase and HA were successfully incorporated into the PRINT particles and
delivered using the same strategy. The LPP particles were also shown to protect the RNA
replicon effectively against RNase A. Future work will focus on investigation of in vivo
delivery efficiency and immunogenicity.
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(a) Agarose gel of RNA replicon before and after particle crosslinking. 1: RNA ladder, 2:
untreated RNA 200 ng, 3: untreated RNA 100 ng, 4: RNA replicon extracted out 37.5 µg of
blank BSA particles, 5:RNA replicon extracted out of 37.5 µg of BSA particles fabricated at
148°C, 6: RNA replicon extracted out of 37.5 µg of BSA particles fabricated at 60°C. (b).
Relative absorbance obtained from CAT ELISA. The absorbance from un-treated cells (cells
only) were defined as 1. Error bars= mean + SD.
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(a) Scanning electron microscope (SEM) image of DIC-crosslinked particles containing
CAT RNA replicon, image was taken after incubation with PBS, scale bar stands for 10 µm.
(b) Agarose gel of RNA replicon before and after particle crosslinking: lane 1: RNA marker,
2: untreated RNA replicon 200 ng, 3: untreated RNA replicon 100 ng, 4: untreated RNA
replicon 50 ng, 5: RNA replicon extracted out of 37.5 µg of BSA particles before
crosslinking reaction, 6: RNA replicon extracted out of 75 µg of BSA particles after cross-
linking reaction.
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CAT protein concentration generated from cells. Black bars: CAT RNA replicon standards
delivered by TransIT, hatched bars: DIC-crosslinked LPP particles containing CAT RNA
replicon, square pattern bars: OEDIC-crosslinked LPP particles containing CAT RNA
replicon. Based on quantification results, 60, 30 and 10 µg/mL of particles contain 900, 450,
and 150 ng/mL of RNA respectively. Error bars= mean + SD.
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Confocal image of CAT protein. (A) BSA particles containing CAT RNA replicon cross-
linked with DIC, 30 µg/mL. (B) BSA particles containing CAT RNA replicon cross-linked
with OEDIC, 30 µg/mL. The red represents the CAT protein and the green represents
PRINT particles. The scale bar represents 10 µm.
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Viability of Vero cells dosed with DOTAP/DOPE lipids only (black bars, the ratio of
DOTAP:DOPE=80:20) and LPP particles (hatched bars). Cells were dosed with samples for
4h followed by removal of particles and 24h incubation at 37 °C. Based on HPLC-ELSD
quantification results, 10, 30 and 60 µg/mL of LPP particles contains 0.006, 0.018 and 0.036
mg/mL of DOTAP/DOPE lipids respectively. Error bars= mean + SD.
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(a) Relative bioluminesence generated by LPP particles on Vero cells. The luminescence
generated by untreated cells is defined as 1. Black: Luciferase (LUC) RNA replicon
standards delivered by TransIT, orange: LPP particles (30 µg/mL) containing Luciferase
RNA replicon (450 ng/mL). Error bars= mean + SD. (b) Confocal image of luciferase
protein, Vero cells for all samples are over 90% confluent in 6-well plate : (A) RNA
replicon (150 ng/mL) transfected with TransIT , (B) PRINT particles (10 µg/mL ) containing
RNA replicon (150 ng/mL) dosed with TransIT. (C) LPP particles (10 µg/mL) containing
luciferase RNA replicon (150 ng/mL), (D) LPP particles (30 µg/mL) containing luciferase
RNA replicon(450 ng/mL). The green represents the luciferase protein. The scale bar
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represents 100 µm. (c) Relative luminesence generated by PRINT particles on A549 cells.
The luminescence generated by untreated cells is defined as 1. Black: Luciferase (LUC)
RNA replicon standards delivered by TransIT, orange: DIC-crosslinked BSA particles
containing Luciferase RNA replicon. Error bars= mean + SD.
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Confocal image of HA protein. The red fluorescence represents the HA protein, the green
represents particles. Particles dosed to Vero cells at 30 µg/mL. Scale bar represents 30 µm.
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